NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Pharmacist-led Intervention for Injectable HIV Treatment for Women With Health-related Social Needs

Active Not RecruitingPhase 2

Sponsor: Yale University

Conditions: Hiv

Interventions: Collaborative drug therapy management model, Cabotegravir/Rilpivirine

Countries: United States

This study addresses real-world use of long-acting injectable cabotegravir/rilpivirine (CAB/RPV LA) by evaluating implementation and clinical outcomes of a pharmacist-led collaborative drug therapy management model (CDTM+) that will be expanded for telehealth outreach to women with health-related social needs (HRSN).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Living with diagnosed HIV
* Receiving HIV care-related services from Yale New Haven Health (YNHH)
* Currently on oral ART and virally suppressed for at least 6 months (from electronic health review).
* Have experienced at least one HRSN: a) homelessness or housing insecurity; b) food insecurity; c) criminal legal system involvement; OR d) substance use in the past 3 years (from self-report at screening).
* Able to converse comfortably in English or Spanish

Exclusion Criteria:

* Unable or unwilling to complete informed consent (e.g., have a conservator of person)
* Have initiated CAB/RPV oral lead-in prior to enrollment.
* Have a contraindication to CAB/RPV LA per label.
* Have known or suspected resistance to CAB/RPV
* Pregnant or breast-feeding

Locations (1)

New Haven, Connecticut, United States